Similar Papers

Paper Title
Journal
Date
Author
Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Xingsheng Hu ... Chengping Hu
Cancer Biology and Medicine | VOL. 17
Xingsheng Hu, et. al.Xingsheng Hu ... Chengping Hu
01 Jan 2020
Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC
Yilong Wu ... Yan Sun
Chinese journal of oncology | VOL. 36
Yilong Wu, et. al.Yilong Wu ... Yan Sun
01 Jan 2014
Clinical outcomes of various resistance mechanisms of osimertinib in Chinese advanced non-small cell lung cancer patients.
Puyuan Xing ... Jing Lin
Journal of Clinical Oncology | VOL. 37
Puyuan Xing, et. al.Puyuan Xing ... Jing Lin
20 May 2019
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
Si-Yang Liu ... Jun-Yi Ye
Biomarker Research | VOL. 8
Si-Yang Liu, et. al.Si-Yang Liu ... Jun-Yi Ye
25 Jun 2020
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer
Baptiste Abbar ... Brigitte Autran
Journal of Thoracic Oncology | VOL. -
Baptiste Abbar, et. al.Baptiste Abbar ... Brigitte Autran
01 Feb 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. 20
--
01 Feb 2025
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
Baohui Han ... Yusheng Wu
Journal of Thoracic Oncology | VOL. -
Baohui Han, et. al.Baohui Han ... Yusheng Wu
01 Feb 2025
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li ... Yi-Long Wu
Journal of Thoracic Oncology | VOL. -
Yang-Si Li, et. al.Yang-Si Li ... Yi-Long Wu
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.